Midazolam
Injection
Current Active — Day 2233
Moderate impact — Limited manufacturing base (2 known suppliers); substitute sourcing may be constrained.
FDA shortage record
- Substance
- Midazolam
- Manufacturers / suppliers
-
- Hikma Pharmaceuticals USA Inc.
- Hikma Pharmaceuticals USA, Inc.
- Dosage form
- Injection
- Presentation
- Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)
- Route(s)
- INTRAMUSCULAR, INTRAVENOUS
- Therapeutic category
- Anesthesia, Neurology
- Package NDC
0641-6060-10- Initially posted
- 04/02/2020
- Days on shortage list
- 2233
- Current FDA status
- Current
- Shortage entries (current dataset)
- 2 records for Midazolam
Reason and context
Additional lots are scheduled to be manufactured. Product will be made available as it is released.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-631-2174.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
575d8bf0-7af7-427c-a231-966e2a5e070d). - FDA UNII identifier:
W7TTW573JJ. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.